Under way, not recruiting
Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2)
NCT06167291 · M.D. Anderson Cancer Center · Updated 7 Oct 2026
- What is being tested
- Arm 1- Ipsilateral
- For
- Oropharyngeal Neoplasms; Robotic Surgery and/or Radiotherapy; Lymphoscintigraphy
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years and older. About 8 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 19 April 2024, ends 9 Dec 2027. Registered 12 Dec 2023.
- Results
- None posted yet.
In the researchers' words
To test a new radiation treatment design based on where your cancer is located. Most participants with oropharyngeal cancer are treated with radiation to both sides of the neck. However, for participants with oropharyngeal cancer on one side of the neck, receiving radiation to both sides of the neck may result in increased side effects and radiation exposure. This study is testing the safety and effectiveness of an approach that involves radiation to only one side of the neck in an effort to reduce the overall amount of radiation given and decrease the amount of side effects you may experience.
Sites
- MD Anderson Cancer CenterHouston, Texas, United States